The Food Safety and Standards Authority of India (FSSAI) has commissioned a quality check on MDH and Everest products. This follows complaints that several popular spice mixes of the two leading brands contained traces of ethylene oxide more than the permissible levels, official sources said. This move by FSSAI comes after Hong Kong and Singapore recalled variants of the two masala majors' products in their countries.
The anti-depressant drug market in the US is primarily ruled by Effexor XR (Venlafaxine) of Wyeth (now owned by Pfizer).
The company has already received approval from the US Food & Drug Administration for marketing clarithromycin tablets.
Lupin Pharmaceuticals Inc, a wholly owned subsidiary of Mumbai-based Lupin Ltd, has forayed into the US pediatric segment by inking an agreement with Allergan Inc to promote 'Zymar' in that country.
Lupin Ltd received US Food & Drug Administration's approval for its abbreviated new drug application for Cefuroxime Axetil tablets.
The company has received the tentative approval from the US Food & Drug Administration to manufacture and market these combination tablets in strengths of 600mg/300mg/ 300mg, a statement by Aurobindo Pharma said.
The FDA has been tightening its monitoring of Indian pharma majors over compliance issues. Surprise plant inspections and import alerts have been frequent outcomes
The rap from both the US and UK drug regulators, including the latest one from the latter, has hit the scrip.
.jpg)
To focus on molecules at advanced stage of development; move to impact 200 scientists.
Broader markers outperformed their larger peers.
Expectations of strong results, consistent performance and investors preference for stocks in the defensive space help the sector outshine broader markets.
Samvat 2072: Auto sector could see faster recovery
Most Asian markets ended with gains.
The Indian Pharmaceutical Alliance has approached regulator for a dialogue to understand the concern raised by it
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
The S&P BSE Sensex ended down 371 points at 24,966 and the Nifty50 closed 101 points lower at 7,615.
Fear factors weights on markets, Sensex, Nifty struggle to keep pace.
Rate-sensitive sectors like banks, auto and realty witnessed strong buying demand in trades today
Sensex, Nifty put up a good show in closing trade.
Market breadth continued to remain strong, with 1899 gainers and 674 losers on the BSEs.
The 30-share Sensex ended up 292 points at 29,571 and the 50-share Nifty closed up 75 points at 8,910.
The S&P BSE Sensex ended 46 points lower at 24,824 and Nifty50 settled at 7,555, down by 8 points after hitting intra-day high of 7,600.45.
Jammu and Kashmir MLA Ramesh Arora wants momos banned, but are they really unhygienic and harmful?
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances